NCT06256549View on ClinicalTrials.gov

A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

272

Participants

Timeline

Start Date

August 9, 2023

Primary Completion Date

July 20, 2024

Study Completion Date

July 20, 2024

Conditions
Type 2 Diabetes
Interventions
DRUG

GZR18

Titrated to low dose or middle or high dose

DRUG

Semaglutide

Titrated to 1.0 mg once a week

Trial Locations (1)

Unknown

Gan & Lee Pharmaceuticals Co., Ltd, Beijing

Sponsors
All Listed Sponsors
lead

Gan and Lee Pharmaceuticals, USA

INDUSTRY